Möchten Sie immer auf dem neuesten Stand bleiben?

Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between...

Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the...

BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...

WINNIPEG, Manitoba, 09 déc. 2024 (GLOBE NEWSWIRE) -- Dans le cadre de son engagement visant à contribuer au renforcement de la résilience face aux effets croissants des changements climatiques,...

WINNIPEG, Manitoba, Dec. 09, 2024 (GLOBE NEWSWIRE) -- As part of its commitment to helping build resilience against the growing impacts of climate change, Wawanesa Insurance is pleased to announce...

Winnipeg, Dec. 09, 2024 (GLOBE NEWSWIRE) -- As part of its commitment to helping build resilience against the growing impacts of climate change, Wawanesa Insurance is pleased to announce four...

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key...

Atlanta, GA, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Pictured: (Left to right) Brooke Feldman, Tim Baldus, Laura Watkins, Lori Lane, Anna Bailey, DeAnn Golden Atlanta, GA: The Greater Atlanta...

The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by Anna Jaques Hospital.

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were...